Literature DB >> 15613114

Reversal of heart failure in thalassemia major by combined chelation therapy: a case report.

M Tsironi1, S Deftereos, P Andriopoulos, D Farmakis, J Meletis, A Aessopos.   

Abstract

In patients with thalassemia major (TM) who are non-compliant with long-term desferrioxamine (DFO) chelation, survival is limited mainly because of cardiac complications of transfusional hemosiderosis. Combined chelation therapy with DFO and deferiprone has maximized the efficacy of the therapy and reduced cardiological complications. The aim of this report is to present the results of this combination in a desperate case of heart failure.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15613114     DOI： 10.1111/j.1600-0609.2004.00335.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN： 0902-4441            Impact factor:   2.997


  13 in total

1.  Incorporation of L-lysine and 2,2'-dipyridyl in the growth media promotes desferrioxamine E production by an actinobacterium.

Authors:  Ismini Nakouti; Glyn Hobbs
Journal:  World J Microbiol Biotechnol       Date:  2013-07-10       Impact factor: 3.312

Review 2.  Beta-thalassemia.

Authors:  Renzo Galanello; Raffaella Origa
Journal:  Orphanet J Rare Dis       Date:  2010-05-21       Impact factor: 4.123

3.  Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit.

Authors:  Vassilios Ladis; Giorgos Chouliaras; Vasilios Berdoukas; Panagiotis Moraitis; Kirykos Zannikos; Eleni Berdoussi; Christos Kattamis
Journal:  Eur J Haematol       Date:  2010-08-30       Impact factor: 2.997

4.  Complete hematopoietic recovery after continuous iron chelation therapy in a patient with severe aplastic anemia with secondary hemochromatosis.

Authors:  Soo-Jeong Park; Chi-Wha Han
Journal:  J Korean Med Sci       Date:  2008-04       Impact factor: 2.153

5.  Major causes of hospital admission in Beta thalassemia major patients in southern iran.

Authors:  Mehran Karimi; Vahid Emadmarvasti; Jacob Hoseini; Lotfolah Shoja
Journal:  Iran J Pediatr       Date:  2011-12       Impact factor: 0.364

6.  Iron chelation therapy in thalassemia syndromes.

Authors:  Paolo Cianciulli
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-12-29       Impact factor: 2.576

7.  Cardiac function and iron chelation in thalassemia major and intermedia: a review of the underlying pathophysiology and approach to chelation management.

Authors:  Athanasios Aessopos; Vasilios Berdoukas
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-07-18       Impact factor: 2.576

8.  The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study.

Authors:  Vasilios Berdoukas; Giorgos Chouliaras; Panagiotis Moraitis; Kirykos Zannikos; Eleni Berdoussi; Vassilios Ladis
Journal:  J Cardiovasc Magn Reson       Date:  2009-06-28       Impact factor: 5.364

9.  Treating thalassemia major-related iron overload: the role of deferiprone.

Authors:  Vasilios Berdoukas; Kallistheni Farmaki; Susan Carson; John Wood; Thomas Coates
Journal:  J Blood Med       Date:  2012-10-19

Review 10.  The heart in transfusion dependent homozygous thalassaemia today--prediction, prevention and management.

Authors:  Athanassios Aessopos; Vasilios Berdoukas; Maria Tsironi
Journal:  Eur J Haematol       Date:  2007-12-10       Impact factor: 2.997
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.